

# John A Thompson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2812787/john-a-thompson-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

156  
papers

22,979  
citations

59  
h-index

151  
g-index

165  
ext. papers

26,477  
ext. citations

8.7  
avg, IF

6.3  
L-index

#	Paper	IF	Citations
156	Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study.. <i>Supportive Care in Cancer</i> , <b>2022</b> , 30, 3829	3.9	0
155	Neoantigen-specific CD4 T'cells in human melanoma have diverse differentiation states and correlate with CD8 T'cell, macrophage, and B cell function.. <i>Cancer Cell</i> , <b>2022</b> , 40, 393-409.e9	24.3	2
154	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors <b>2021</b> , 9,		2
153	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study <b>2021</b> , 9,		6
152	A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , <b>2021</b> , 26, 182-e361	5.7	9
151	Management of post-operative delirium following stereoelectroencephalography electrode placement for drug resistant epilepsy: Lessons learned from two case reports. <i>Epilepsy and Behavior Reports</i> , <b>2021</b> , 16, 100438	1.3	
150	Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 896-904	7.3	2
149	Eosinophilic fasciitis as a paraneoplastic syndrome in melanoma. <i>JAAD Case Reports</i> , <b>2021</b> , 17, 49-51	1.4	0
148	Xerostomia: an immunotherapy-related adverse effect in cancer patients. <i>Supportive Care in Cancer</i> , <b>2021</b> , 1	3.9	2
147	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy <b>2020</b> , 8,		45
146	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5086-5091	12.9	11
145	Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 19, 700-708	7.3	3
144	Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol. <i>BMJ Open</i> , <b>2020</b> , 10, e037857	3	1
143	Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board. <i>Targeted Oncology</i> , <b>2020</b> , 15, 541-548	5	5
142	Immunologic adverse events from immune checkpoint therapy. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2020</b> , 34, 101511	5.3	2
141	A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. <i>Cancer</i> , <b>2019</b> , 125, 1124-1132	6.4	20
140	Current Applications of Diffusion Tensor Imaging and Tractography in Intracranial Tumor Resection. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 426	5.3	30

139	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <i>Nature Reviews Clinical Oncology</i> , <b>2019</b> , 16, 563-580	19.4	584
138	Management of Immunotherapy-Related Toxicities, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 255-289	7.3	246
137	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 367-402	7.3	195
136	Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 750-757	7.3	52
135	New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. <i>Lancet Oncology</i> , <b>2019</b> , 20, e54-e64	21.7	93
134	Guidelines of care for the management of primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 208-250	4.5	202
133	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , <b>2019</b> , 125, 18-44	6.4	15
132	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1805-1815	12.9	38
131	Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 457-463.e2	4.5	211
130	Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in-transit melanoma. <i>Journal of Cutaneous Pathology</i> , <b>2018</b> , 45, 864-868	1.7	3
129	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 <b>2018</b> , 6, 44		39
128	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 916-929	21.7	83
127	Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 1563-1568	15.9	62
126	Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC). <i>Journal of Immunotherapy and Precision Oncology</i> , <b>2018</b> , 1, 46-48	0.6	
125	A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1525-1535	12.9	95
124	Reply to D.L. Kimpel et al. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2744	2.2	
123	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1714-1768	2.2	1740
122	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , <b>2018</b> , 14, 247-249	3.1	150

121	Membrane Dynamics and Regulation of Subcellular Changes during Senescence <b>2018</b> , 39-68		
120	Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report <b>2018</b> , 6, 82		21
119	Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial. <i>European Journal of Cancer</i> , <b>2018</b> , 101, S34	7.5	5
118	New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2018</b> , 16, 594-596	7.3	95
117	Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4399-4406	12.9	23
116	A second chance for success with BRAF and MEK inhibitors in melanoma. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 418-419	21.7	2
115	Academic Cancer Center Phase I Program Development. <i>Oncologist</i> , <b>2017</b> , 22, 369-374	5.7	
114	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1202-1210	21.7	161
113	The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3027-3027	2.2	12
112	Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9522-9522	2.2	5
111	KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9545-9545	2.2	7
110	A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS3101-TPS3101	2.2	2
109	Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 510-510	2.2	4
108	Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. <i>Journal of Experimental Medicine</i> , <b>2016</b> , 213, 1133-9	16.6	55
107	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 406-414	3.3	8
106	T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3787-3795	2.2	66
105	Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2855-64	12.9	57
104	Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. <i>Oncologist</i> , <b>2016</b> , 21, 402-3	5.7	2

103	Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3013-3013	2.2	4
102	First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3079-3079	2.2	20
101	Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9525-9525	2.2	2
100	Recurrent Inhibition to the Medial Nucleus of the Trapezoid Body in the Mongolian Gerbil ( <i>Meriones Unguiculatus</i> ). <i>PLoS ONE</i> , <b>2016</b> , 11, e0160241	3.7	6
99	Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 450-73	7.3	165
98	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 945-58	7.3	66
97	Major Changes in Systemic Therapy for Advanced Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 638-40	7.3	7
96	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2542-52	59.2	828
95	A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. <i>Investigational New Drugs</i> , <b>2016</b> , 34, 439-49	4.3	71
94	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 652-63	4.3	32
93	Treatment options expanding for advanced melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 673-5	7.3	1
92	Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2503-2503	2.2	13
91	Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3009-3009	2.2	12
90	Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study <b>2014</b> , 2, 2		33
89	Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2099-107	2.2	83
88	A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2099-107	7.5	16
87	Melanoma: immune checkpoint blockade story gets better. <i>Lancet, The</i> , <b>2014</b> , 384, 1078-9	4.0	9
86	Melanoma, version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2014</b> , 12, 621-23	7.3	52

85	Inhibitory projections from the ventral nucleus of the trapezoid body to the medial nucleus of the trapezoid body in the mouse. <i>Frontiers in Neural Circuits</i> , <b>2014</b> , 8, 83	3.5	34
84	Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series <b>2014</b> , 2, 33		38
83	Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 1246-574-3		75
82	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 1056-64	14.4	146
81	A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. <i>Cancer</i> , <b>2014</b> , 120, 1647-55	6.4	25
80	Fast neutron radiotherapy for primary mucosal melanomas of the head and neck. <i>Head and Neck</i> , <b>2014</b> , 36, 1162-7	4.2	18
79	Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 981-7	12.5	8
78	Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2569-2569	2.2	9
77	Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refractory B-cell malignancies.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS8616-TPS8616	2.2	2
76	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. <i>Nature Reviews Clinical Oncology</i> , <b>2013</b> , 10, 588-98	19.4	145
75	Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e370-2	2.2	18
74	Melanoma, version 2.2013: featured updates to the NCCN guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2013</b> , 11, 395-407	7.3	112
73	SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 368-368	2.2	1
72	Relationship between biomarkers and everolimus efficacy in the phase III RECORD-1 trial of patients with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 352-352	2.2	
71	Ten years of progress in melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2012</b> , 10, 932-5	7.3	2
70	Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 4592-7	11.5	127
69	Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1371-7	2.2	223
68	Systemic therapy for metastatic melanoma in 2012: dawn of a new era. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2012</b> , 10, 403-12	7.3	22



67	Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. <i>Journal of Immunotherapy</i> , <b>2012</b> , 35, 73-7	5	24
66	Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8504-8504	2.2	10
65	MLN9708, an investigational proteasome inhibitor, in patients (pts) with solid tumors: Updated phase I results.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e13603-e13603	2.2	1
64	Novel Cytokines for Immunotherapy of Melanoma <b>2012</b> , 333-351		
63	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). <i>European Journal of Cancer</i> , <b>2011</b> , 47, 1476-83	7.5	157
62	Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. <i>Expert Opinion on Biological Therapy</i> , <b>2011</b> , 11, 763-73	5.4	7
61	Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e237-40	2.2	116
60	Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7765-75	12.9	36
59	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5539-47	12.9	161
58	Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2402-8	12.9	60
57	A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2010</b> , 33, 495-9	2.7	72
56	Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 1396-405	4	81
55	Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. <i>Cancer</i> , <b>2010</b> , 116, 424-31	6.4	16
54	Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. <i>Cancer</i> , <b>2010</b> , 116, 4256-65	6.4	904
53	Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. <i>PLoS ONE</i> , <b>2009</b> , 4, e4749	3.7	81
52	A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5591-8	12.9	457
51	Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6207-12	2.2	36
50	Metastatic renal cell carcinoma: current standards of care. <i>Clinical Journal of Oncology Nursing</i> , <b>2009</b> , 13 Suppl, 8-12	1.1	1

49	Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. <i>Clinical Genitourinary Cancer</i> , <b>2009</b> , 7, E58-65	3.3	40
48	Mechanism of action of everolimus in renal cell carcinoma. <i>Medical Oncology</i> , <b>2009</b> , 26, 32-39	3.7	29
47	Temsirolimus in patients with advanced renal cell carcinoma: an overview. <i>Advances in Therapy</i> , <b>2009</b> , 26, 55-67	4.1	17
46	Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins. <i>Cancer Immunology, Immunotherapy</i> , <b>2009</b> , 58, 843-54	7.4	19
45	Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3584-90	2.2	1729
44	Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. <i>Journal of Immunotherapy</i> , <b>2009</b> , 32, 203-5	5	66
43	Treatment of metastatic melanoma: an overview. <i>Oncology</i> , <b>2009</b> , 23, 488-96	1.8	283
42	Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2009</b> , 7, 250-75	7.3	106
41	Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2698-703	59.2	702
40	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. <i>Lancet, The</i> , <b>2008</b> , 372, 449-56	4.0	2451
39	Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2034-9	2.2	147
38	C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5260-9	12.9	42
37	Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2008</b> , 8, 1947-53	5.4	9
36	Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9433). <i>Blood</i> , <b>2008</b> , 111, 4048-54	2.2	23
35	Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. <i>Cancer</i> , <b>2007</b> , 110, 2269-75	6.4	11
34	Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2078-85	2.2	74
33	Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 1188-94	2.2	63
32	A phase II study of depsipeptide in refractory metastatic renal cell cancer. <i>Clinical Genitourinary Cancer</i> , <b>2006</b> , 5, 57-60	3.3	130



31	A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. <i>Investigational New Drugs</i> , <b>2006</b> , 24, 89-94	4.3	8
30	Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy with Interleukin-2 Versus Observation for Patients with Non-Hodgkin's Lymphoma: Results of a Phase III Randomized Trial by the Southwest Oncology Group (SWOG 9438). <i>Blood</i> , <b>2006</b> , 108, 326-328	2.2	1
29	Identification of A Well-tolerated Outpatient Regimen of Interleukin-21 (IL-21) in Patients With Metastatic Melanoma and Renal Cell Carcinoma (RCC). <i>Journal of Immunotherapy</i> , <b>2005</b> , 28, 641-642	5	1
28	The absolute bioavailability of oral vinorelbine in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2005</b> , 56, 578-84	3.5	20
27	Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3003-15	2.2	291
26	Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 7799-811	12.9	74
25	An evidence-based staging system for cutaneous melanoma. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2004</b> , 54, 131-49; quiz 182-4	220.7	270
24	Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2004</b> , 58, 984-90	4	198
23	New TNM melanoma staging system: linking biology and natural history to clinical outcomes. <i>Journal of Surgical Oncology</i> , <b>2003</b> , 21, 43-52		90
22	The revised American Joint Committee on Cancer staging system for melanoma. <i>Seminars in Oncology</i> , <b>2002</b> , 29, 361-9	5.5	32
21	Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2058-66	2.2	186
20	Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2067-75	2.2	175
19	Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. <i>Journal of the American Academy of Dermatology</i> , <b>2002</b> , 47, 140-5	4.5	26
18	Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3622-34	2.2	2077
17	Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3635-48	2.2	2173
16	Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. <i>Journal of Interferon and Cytokine Research</i> , <b>2001</b> , 21, 257-63	3.5	81
15	A new American Joint Committee on Cancer staging system for cutaneous melanoma. <i>Cancer</i> , <b>2000</b> , 88, 1484-91	6.4	331
14	Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. <i>Circulation</i> , <b>2000</b> , 101, 1362-5	16.7	231

13	Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. <i>Journal of Experimental Medicine</i> , <b>2000</b> , 192, 1637-44	16.6	374
12	Extracellular FGF-1 inhibits cytoskeletal organization and promotes fibroblast motility. <i>Growth Factors</i> , <b>2000</b> , 18, 93-107	1.6	8
11	Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer. <i>Cancer Investigation</i> , <b>2000</b> , 18, 417-21	2.1	9
10	Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 2521-9	2.2	166
9	Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. <i>Nature Medicine</i> , <b>1999</b> , 5, 677-85	50.5	947
8	Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive Pulmonary Aspergillosis. <i>Blood</i> , <b>1999</b> , 94, 3273-3276	2.2	1
7	Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study. <i>Journal of Immunotherapy</i> , <b>1998</b> , 21, 440-6	5	32
6	The effects of pentoxifylline on the generation of human lymphokine-activated killer cell cytotoxicity. <i>Journal of Immunotherapy</i> , <b>1993</b> , 13, 84-90	5	2
5	Adverse reactions to intravenous contrast media in patients treated with interleukin-2. <i>Journal of Immunotherapy</i> , <b>1993</b> , 13, 208-12	5	38
4	Growth and autologous tumor lysis by tumor-infiltrating lymphocytes from metastatic melanoma expanded in interleukin-2 or interleukin-2 plus interleukin-4. <i>Journal of Immunotherapy</i> , <b>1993</b> , 14, 322-8	5	6
3	Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects. <i>Cancer Immunology, Immunotherapy</i> , <b>1987</b> , 25, 47-53	7.4	39
2	The treatment of hairy cell leukemia with recombinant alfa interferon: a multi-institutional study. <i>Investigational New Drugs</i> , <b>1987</b> , 5 Suppl, S5-8	4.3	2
1	Interferon in the treatment of hairy cell leukemia. <i>Cancer</i> , <b>1987</b> , 59, 605-9	6.4	21